APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

Topriceanu, Constantin-Cristian; Shah, Mit; Webber, Matthew; Chan, Fiona; Shiwani, Hunain; Richards, Marcus; Schott, Jonathan; Chaturvedi, Nishi; Moon, James C.; Hughes, Alun D.; Hingorani, Aroon D.; O’Regan, Declan P.; Captur, Gabriella

doi:10.1186/s12872-024-03808-z

BMC Cardiovascular Disorders

Table 6 Associations between APOE ε4 genotypes and echocardiographic data in older age by comparing non-APOE ε4 (ε2ε2, ε2ε3, ε2ε3) with APOE ε4 (ε2ε4, ε3ε4 and ε4ε4) genotypes in UK Biobank

From: APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

s		Model 1 (unadjusted)			Model 2 (adjusted for age, sex, and SEP)		Model 3 (Model 2 + BMI)		Model 4 (Model 2 + CVD)		Model 5 (Model 2 + diabetes)		Model 6 (Model 2 + high cholesterol)		Model 7 (Model 2 + HT)
Outcome	APOE ε4 status	n	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value
EF	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
EF	APOE ε4 carriers	32,644	1.00 (1.00, 1.00)	0.916	1.00 (1.00, 1.00)	0.453	1.00 (1.00, 1.00)	0.902	1.00 (1.00, 1.00)	0.836	1.00 (1.00, 1.00)	0.830	1.00 (1.00, 1.00)	0.840	1.00 (1.00, 1.00)	0.914
L_PDSR	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
L_PDSR	APOE ε4 carriers	32,505	1.02 (1.00, 1.03)	0.045	1.00 (0.99, 1.02)	0.657	1.02 (1.00, 1.03)	0.063	1.02 (1.00, 1.03)	0.032	1.01 (1.00, 1.03)	0.095	1.02 (1.01, 1.04)	0.002	1.02 (1.00, 1.03)	0.059
R_PDSR	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
R_PDSR	APOE ε4 carriers	32,505	0.95 (0.90, 1.00)	0.05	0.98 (0.94, 1.04)	0.536	0.96 (0.91, 1.01)	0.102	0.95 (0.90, 1.00)	0.034	0.96 (0.91, 1.01)	0.106	0.93 (0.88, 0.98)	0.004	0.95 (0.90, 1.00)	0.063
LVmass	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
LVmass	APOE ε4 carriers	32,644	1.00 (0.99, 1.01)	0.568	1.00 (1.00, 1.01)	0.242	1.00 (0.99, 1.01)	0.798	1.00 (0.99, 1.00)	0.350	1.00 (0.99, 1.01)	0.815	1.00 (0.99, 1.00)	0.127	1.00 (0.99, 1.01)	0.695
MCF	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
MCF	APOE ε4 carriers	32,643	1.01 (1.00, 1.01)	0.020	1.01 (1.00, 1.01)	0.080	1.00 (1.00, 1.01)	0.079	1.01 (1.00, 1.01)	0.006	1.00 (1.00, 1.01)	0.058	1.01 (1.01, 1.01)	0.0001	1.01 (1.00, 1.01)	0.034
PWT	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
PWT	APOE ε4 carriers	32,605	1.00 (0.99, 1.00)	0.094	1.00 (1.00, 1.00)	0.881	1.00 (1.00, 1.00)	0.448	1.00 (0.99, 1.00)	0.037	1.00 (1.00, 1.00)	0.257	0.99 (0.99, 1.00)	0.002	1.00 (1.00, 1.00)	0.132
IVS	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
IVS	APOE ε4 carriers	32,605	1.00 (0.99, 1.00)	0.128	1.00 (1.00, 1.00)	0.986	1.00 (1.00, 1.00)	0.537	1.00 (0.99, 1.00)	0.056	1.00 (0.99, 1.00)	0.281	1.00 (0.99, 1.00)	0.003	1.00 (0.99, 1.00)	0.179

All reported analyses here consisted of generalized linear models with gamma distribution and log link, except for the longitudinal and radial PDSR analyses where generalized linear models with Gaussian distribution and identity link were used instead. Significant p-values are highlighted in bold. Abbreviations as in Tables 1 and 2

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com